Abstract
Introduction: the American Trypanosomiasis or Chagas disease is one of the parasitic diseases that has most epidemiological importance in Latin America and is transmitted by blood-sucking insects and it is caused by the protozoan Trypanosoma cruzi. This disease presents itself in two important clinical phases: acute and chronic. Objective: submit an update on the Chagas disease, specifying key information like its definition, etiology, life cycle, epidemiology, diagnosis, clinical manifestations and treatment. Methodology: we reviewed a great amount of literature found in databases and virtual libraries such as: OvidSP, Medline, EBSCO host, Pubmed, Uptodate, New England Journal of Medicine, Cochrane and SciELO, using words like Chagas cardiomyopathy, Chagas disease, Trypanosoma cruzi, Insects. Discussion: the most common type of cardiac damage in chronic Chagas is the cardiomyopathy, whose clinical diagnosis and prognosis is linked to a continuous variety of monitoring methods such as echocardiography and electrocardiograms, for laboratory detection clinically necessary to identify the phase of the disease to select the diagnostic test be more sensitive. Now from a therapeutic point of view, there is a low amount of pharmacological alternatives for the eradication of the parasite, reason for which it is important to have prevention models for the Colombian population in general. Conclusion: understanding and knowing the disease in all its aspects is a fundamental tool in the creation of new prevention options and treatments to control this type of disease, which currently affects a big amount of the population found in urban areas all over the world but most importantly in Latin America, and this way helping improve the quality of life of each patient. MÉD.UIS. 2015;28(1):81-90.
Keywords: Chagas Cardiomyopathy. Chagas Disease. Trypanosoma cruzi. Insects.
References
Albajar P, Dias JC. Advancing the Treatment for Chagas’ Disease. N Engl J Med. 2014;370:1942-3.
Bern C. Antitrypanosomal Therapy for Chronic Chagas’ Disease. N Engl J Med. 2011;364:2527-34.
Quijano I, Dumonteil E. Advances and challenges toward a vaccine against Chagas disease. Hum vaccin. 2011;7(11):1184-91.
Ribeiro MP, Moraes A, Oliveira LF, Cuba MB, Oliveira I, Castellano LR, et al. Autonomic nervous system modulation affects the inflammatory immune response in mice with acute Chagas disease. Exp Physiol. 2012;97(11):1186-202.
. Muñoz SG, Haberland A, Bartel S, Araujo R, Valda G, DuchenD, et al. Cardiac Troponin T Measured With a Highly Sensitive Assay for Diagnosis and Monitoring of Heart Injury in Chronic Chagas Disease. Arch Pathol Lab Med. 2011;(135):243-8.
Santos FM, Lima WG, Gravel AS, Martin s TA, Talvani A,TorresRM, et al. Cardiomyopathy prognosis after benznidazole treatment in chronic canine Chagas’ disease. J Antimicrob Chemother. 2012;67(8):1987-95. Epub 7 May 2012.
Instituto Nacional de Salud. Vigilancia y Análisis del Riesgo en Salud Púclica. Protocolo de Vigilancia en Salud Pública Chagas. 2014;01:1-26.
Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis. 2012;25(4):450-7.
Maya JD, Orellana M, Ferreira J, Kemmerling U, López-Muñoz R, Morello A. Chagas disease: Present status of pathogenic mechanisms and chemotherapy. Biol Res. 2010;43(3):323-31. Epub 30 Nov 2010.
Machado FS, Jelicks LA, Kirchhoff LV, Shirani J, Nagajyothi F, Mukherjee S, et al. Chagas heart disease: report on recent developments. Cardiol Rev. 2012;20(2):53-65.
Haberland A, Munoz SG, Wallukat G, Ziebig R, Schimke I. Chronic Chagas disease: from basics to laboratory Medicine. Clin Chem Lab Med. 2013;51(2):271–94.
Muñoz SG, Haberland A, Wallukat G, Schimke I. Chronic Chagas’ heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine. Heart Fail Rev. 2012;17:45-64.
Ministerio de la Protección Social, Instituto Nacional de Salud, Organización Panamericana de la Salud OPS/OMS. Guía para
la Atención Clínica Integral del paciente con enfermedad de Chagas. 2010;1-81.
Muratore C, Baranchuk A. Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy. Vasc health and risk manag. 2010;6:593-601.
Machado F, Dutra W, Esper L, Gollob K, Teixeira M, Factor S, et al. Current Understanding of Immunity to Trypanosoma cruzi Infection and Pathogenesis of Chagas Disease. Semin Immunopathol. 2012;34(6): 753-70.
Marques J, Mendoza I, Noya B, Acquatella H, Palacios I, Marques M. ECG Manifestations of the Biggest Outbreak of Chagas Disease due to Oral Infection in Latin-America. Arq Bras Cardiol. 2013;101(3):249-54.
Cedraz SS, Silva PC, Minowa RK, Aragão JF, Silva DV, Morillo C, et al. Electrophysiological characteristics of Chagas disease. einstein(São Paulo). 2013;11(3):291-5.
González JC, Pérez IA, Badell CC, Rodríguez D. Enfermedad de Chagas crónica e insuficiencia cardíaca congestiva en um adulto joven. Medisan. 2014;18(6):862-5.
Barbosa M, Pereira M. Estratificación del riesgo en la enfermedad de Chagas. Rev Esp Cardiol. 2012;65(2):17-21.
Pereira M, Barbosa M, Ribeiro A, Amorim LM, Rocha M. Factores predictivos de la mortalidad en pacientes con miocardiopatía dilatada: importancia de la enfermedad de Chagas como etiología. Rev Esp Cardiol. 2010;63(7):788-97.
Abuhid IM, Pietra ER, Rezende NA. Gammagrafía para Detección de Compromiso Miocárdico en la Forma Indeterminada de la Enfermedad de Chagas. Arq Bras Cardiol. 2010;95(1):30-34.
Andrade JP, Marin JA, Vincenzo AA, Vilas F, Moraes GM, Bacal F, et al. I Directriz Latinoamericana para el Diagnóstico y Tratamiento de la Cardiopatía Chagásica. Resumen Ejecutivo. Arq Bras Cardiol. 2011;96(6):434-42.
Vásquez C, Robledo S, Calle J, Triana O. Identificación de nuevos escenarios epidemiológicos para la enfermedad de Chagas en la región momposina, norte de Colombia. Biomédica (Impr). 2013;33:526-37.
Rocha DB, dos Reis MA, Romano A, Lima SA, Antunes VP, Tostes S, et al. In Situ Expression of Regulatory Cytokines by Heart Inflammatory Cells in Chagas’ Disease Patients with Heart Failure. Clin Dev Immunol. 2012;2012(2012):1-7.
Nagajyothi F, Machado F, Bur leigh B, Jelicks L, SchererP, Mukherjee S, et al. Mechanisms of Trypanosoma cruzi persistence in Chagas Disease. Cell Microbiol. 2012;14(5):634-43.
Burgos JM, Diez M, Vigliano C, Bisio M, Risso M, Duffy T, et al. Molecular Identification of Trypanosoma cruzi DiscreteTyping Units in End-Stage Chronic Chagas Heart Disease and Reactivation after Heart Transplantation. Clin Infect Dis. 2010;51(5):485-95.
Parise M, Hotez P, Slutsker L. Neglected Parasitic Infections in the United States: Needs and Opportunities. Am J Trop Med Hyg. 2014;90(5):783-5.
Marin-Neto JA, Simões MV, Rassi Junior A. Pathogenesis of chronic Chagas cardiomyopathy: the role of coronary microvascular derangements. Rev Soc Bras Med Trop. 2013;46(5):536-41.
Tanowitz H, Machado F, Jelicks L, Shirani J, Campos A, Spray D, et al. Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Prog Cardiovasc Dis. 2009;51(6):524-39.
Alducin C, Rueda E, Medina I, Hernández O, López R, PeñaV, et al. Prevalencia de serología positiva para Trypanosoma cruzi en pacientes con diagnóstico clínico de miocardiopatía dilatada en el Estado de Campeche, México. Arch Cardiol Mex. 2011;81(3):204-7.
Belisário CJ, Leite JV, Diotaiuti L. Profile of the Trypanosoma cruzi vector infestation in Jaboticatubas, State of Minas Gerais, Brazil. Rev Soc Bras Med Trop. 2013;46(6):779-82.
Pedrosa R, Gameiro JH, Magnanini M, Bezerra D, Vergetti K.Prognostic Value of Exercise-Induced Ventricular Arrhythmia in Chagas’ Heart Disease. Pacing Clin Electrophysiol. 2011;34:1492-7.
Molina I, Gómez J, Salvador F, Treviño B, Sulleiro E, Serre N, et al. Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas’ Disease. N Engl J Med. 2014;370:1899-908.
Pavía PX, Roa NL, Uribe AM, Puerta CJ. Seguimiento de paciente con enfermedad de Chagas y Trasplante de corazón mediante las PCR S35-S36 y TcH2AF-R. Biomédica. 201;31(2):178-84.
Martínez-Tovar JG, Rebollar-Téllez EA, Fernández I. Seroprevalenceo f T. cruzi infection in blood donors and Chagas cardiomyopathy in patients from the coal mining region of Coahuila, Mexico. Rev Inst Med Trop Sao Paulo. 2014;56(2):169-74.
Matta JA, Aras R Jr, Bastos CR, Gonçalves C, Martins E. Stroke Correlates in Chagasic and Non-Chagasic Cardiomyopathies.
PLoS One. 2012;7(4):e35116.
Prado CM, Jelicks LA, Weiss LM, Factor SM, Tanowitz HB, Rossi MA. The Vasculature in Chagas Disease. Adv Parasitol. 2011;76:83-99.
Toso A, Vial F, Galanti N. Transmisión de la enfermedad de Chagas por vía oral. Rev Med Chile. 2011;139(2):258-66.
Lescure FX, Le-Loup GL, Freilij H, Develoux M, Paris L, Brutus L, et al. Chagas disease: changes in knowledge and management. Lancet Infect Dis. 2010;10(8):556-70.
Guidobaldi F, May-Concha IJ, Guerenstein PG. Morphology and physiology of the olfactory system of blood-feeding insects. J
Physiol Paris. 2014;108(2-3):96-111.
Bautista-López NL, Morillo CA, Lopez-Jaramillo P, Quiroz R, Luengas C, Silva SY, et al. Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy. Am Heart J. 2013;165(4):558-66.
Geurts N, Opdenakker G, Van PE. Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. Pharmacol
Ther. 2012;133(3):257-79.
Jimenez V , Kemmerling U, Paredes R, Maya JD , Sosa MA, Galanti N. Natural sesquiterpene lactones induce programmed cell death inTrypanosoma cruzi: A new therapeutic target? Phytomedicine. 2014;21(11):1411-8.
Rassi Jr A, Rassi A, Marcondes J. American Trypanosomiasis (Chagas Disease). Infect dis clin North Am. 2012;26:275-91.
Carabarin-Lima A, González-Vásquez MC, Rodríguez-Morales O, Baylón-Pacheco L, Rosales-Encina JL, Reyes-López PA, et al. Chagas disease (American trypanosomiasis) in Mexico: An update. Acta Trop. 2013;127(2):126-35.
Perez C, Lymbery A, Thompson A. Chagas disease: the challenge of polyparasitism? Trends Parasitol. 2014;30(4):176-82.
Pereira MC, Dones W, Morillo C, Encina JJ, Ribeiro AL. Chagas Disease. JACC. 2013;62(9)767-76.
Díaz MV, Miranda MR, Campos-Estrada C, Reigada C, Maya JD, Pereira CA, et al. Pentamidine exerts in vitro and in vivo anti Trypanosoma cruzi activityand inhibits the polyamine transport in Trypanosoma cruzi. Acta Trop. 2014;134:1-9.
Abad-Franch F, Santos WS, Schofield CJ. Research needs for Chagas disease prevention. Acta Trop. 2010;115(1-2):44-54.
Urbina JA. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Trop. 2010;115(1-
:55-68